Radiobismuth for Therapy

Brechbiel, Martin W.; Dadachova, Ekaterina

doi:10.1002/9780470975503.ch13

Cited by 1 publication

(1 citation statement)

References 78 publications

(90 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 212 Bi generator is prepared by loading the 224 Ra onto a cation-exchange resin and 212 Bi eluted using 0.5–2 M HCl or HI. Elution of 212 Pb can be minimized by using lower acid concentration; however, both radionuclides are often eluted and labeled in transient equilibrium. − Interestingly, 212 Bi can also be obtained by isolating gaseous or aqueous 220 Rn; however, these methods have not been further explored due to limited 228 Th availability. − As discussed, the 212 Bi daughter, 208 Tl, emits high-energy, high-intensity gammas and places high shielding requirements on nuclear medicine staff. This is seen as a major drawback to clinical applicability of 212 Bi, and for this reason, 213 Bi is the preferred bismuth radioisotope and will be the focus of further discussion.…”

Section: Bismuthmentioning

confidence: 99%

Radioactive Main Group and Rare Earth Metals for Imaging and Therapy

2018

View full text Add to dashboard Cite

Radiometals possess an exceptional breadth of decay properties and have been applied to medicine with great success for several decades. The majority of current clinical use involves diagnostic procedures, which use either positron-emission tomography (PET) or single-photon imaging to detect anatomic abnormalities that are difficult to visualize using conventional imaging techniques (e.g., MRI and X-ray). The potential of therapeutic radiometals has more recently been realized and relies on ionizing radiation to induce irreversible DNA damage, resulting in cell death. In both cases, radiopharmaceutical development has been largely geared toward the field of oncology; thus, selective tumor targeting is often essential for efficacious drug use. To this end, the rational design of fourcomponent radiopharmaceuticals has become popularized. This Review introduces fundamental concepts of drug design and applications, with particular emphasis on bifunctional chelators (BFCs), which ensure secure consolidation of the radiometal and targeting vector and are integral for optimal drug performance. Also presented are detailed accounts of production, chelation chemistry, and biological use of selected main group and rare earth radiometals.

show abstract